Citadel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,359,613
| Closed | -$19.2M | – | 13178 |
|
|
2025
Q4 | $12.7M | Buy |
1,359,613
+696,400
| +105% | +$5.82M | ﹤0.01% | 2931 |
|
|
2025
Q3 | $4.68M | Sell |
663,213
-40,431
| -6% | -$278K | ﹤0.01% | 4486 |
|
|
2025
Q2 | $4.57M | Sell |
703,644
-635,374
| -47% | -$4.37M | ﹤0.01% | 4271 |
|
|
2025
Q1 | $10.6M | Buy |
1,339,018
+727,705
| +119% | +$7.84M | ﹤0.01% | 2775 |
|
|
2024
Q4 | $7.75M | Buy |
611,313
+127,052
| +26% | +$1.77M | ﹤0.01% | 3303 |
|
|
2024
Q3 | $6.75M | Buy |
484,261
+114,653
| +31% | +$1.64M | ﹤0.01% | 3476 |
|
|
2024
Q2 | $5.09M | Buy |
369,608
+322,343
| +682% | +$4.72M | ﹤0.01% | 3721 |
|
|
2024
Q1 | $781K | Buy |
47,265
+39,998
| +550% | +$599K | ﹤0.01% | 7444 |
|
|
2023
Q4 | $106K | Buy |
7,267
+513
| +8% | +$6.22K | ﹤0.01% | 10858 |
|
|
2023
Q3 | $82.9K | Sell |
6,754
-765,402
| -99% | -$9.98M | ﹤0.01% | 11125 |
|
|
2023
Q2 | $9.22M | Buy |
772,156
+378,072
| +96% | +$4.94M | ﹤0.01% | 2783 |
|
|
2023
Q1 | $5.27M | Buy |
394,084
+387,213
| +5,635% | +$7.56M | ﹤0.01% | 3718 |
|
|
2022
Q4 | $148K | Sell |
6,871
-41,077
| -86% | -$843K | ﹤0.01% | 10629 |
|
|
2022
Q3 | $961K | Sell |
47,948
-11,856
| -20% | -$252K | ﹤0.01% | 7075 |
|
|
2022
Q2 | $1.07M | Sell |
59,804
-51,932
| -46% | -$536K | ﹤0.01% | 6867 |
|
|
2022
Q1 | $1.11M | Buy |
+111,736
| New | +$1.48M | ﹤0.01% | 7466 |
|
Other funds holding DAWN
Citadel Advisors's DAWN Position: Q1 2026 in Review
Citadel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1,359,613 shares — an estimated $19.2M sold.
Citadel Advisors first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $12.7M in Q4 2025. 207 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.
- Citadel Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,359,613 Day One Biopharmaceuticals shares in Q1 2026, an estimated $19.2M.
- Citadel Advisors first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
- Citadel Advisors's Day One Biopharmaceuticals position peaked at $12.7M in Q4 2025.
- 207 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.